|
May 22, 2019
|
FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019 PRINCETON, N.J. , May 22, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the
|
|
|
May 17, 2019
|
PRINCETON, N.J. , May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ( FDA ) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined
|
|
|
May 09, 2019
|
PRINCETON, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari , will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019
|
|
|
May 03, 2019
|
PRINCETON, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla ® (AG200-15), an investigational, once weekly, low-dose hormonal contraceptive patch, will
|
|
|
May 02, 2019
|
Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial
|
|
|
Mar 28, 2019
|
PRINCETON, N.J. , March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 at 3:50
|
|
|
Mar 15, 2019
|
PRINCETON, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation during the 2
|
|
|
Mar 12, 2019
|
Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial
|
|
|
Mar 11, 2019
|
PRINCETON, N.J. , March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tuesday March 19,
|
|
|
Mar 04, 2019
|
PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares of
|
|